✦ LIBER ✦

Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction

✍ Scribed by Chakrabarti, Anjan K.; Feeney, Kristin; Abueg, Cassandra; Brown, David A.; Czyz, Ewa; Tendera, Michal; Janosi, Andras; Giugliano, Robert P.; Kloner, Robert A.; Weaver, W. Douglas; Bode, Christoph; Godlewski, Jacek; Merkely, Bela; Gibson, C. Michael

Book ID: 121076703
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 322 KB
Volume: 165
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2012.12.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE)

✍ Ik-Kyung Jang; Neil J. Weissman; Michael H. Picard; Michael R. Zile; Veronica Pe 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 264 KB

A Randomized, Double-Blind, Placebo-Cont

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: Rationale and Design of the Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI (EVOLVE) Study

✍ Ik-Kyung Jang; Veronica Pettigrew; Michael H. Picard; Peter R. Kowey; Valentin D 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 219 KB

Rationale and design of the Anti-Xa Ther

Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

✍ C. Michael Gibson; Jessica L. Mega; Paul Burton; Shinya Goto; Freek Verheugt; Ch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 428 KB